CN111569068B - 一种有机无机杂化光敏剂及杂化纳米诊疗试剂的制备方法 - Google Patents
一种有机无机杂化光敏剂及杂化纳米诊疗试剂的制备方法 Download PDFInfo
- Publication number
- CN111569068B CN111569068B CN202010407057.9A CN202010407057A CN111569068B CN 111569068 B CN111569068 B CN 111569068B CN 202010407057 A CN202010407057 A CN 202010407057A CN 111569068 B CN111569068 B CN 111569068B
- Authority
- CN
- China
- Prior art keywords
- organic
- photosensitizer
- inorganic hybrid
- preparation
- organic semiconductor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 45
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 21
- 238000003745 diagnosis Methods 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000002105 nanoparticle Substances 0.000 claims abstract description 26
- 239000004065 semiconductor Substances 0.000 claims abstract description 26
- 150000004032 porphyrins Chemical class 0.000 claims abstract description 10
- 229920000734 polysilsesquioxane polymer Polymers 0.000 claims abstract description 7
- 238000000975 co-precipitation Methods 0.000 claims abstract description 5
- 238000000799 fluorescence microscopy Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims description 20
- UVAMFBJPMUMURT-UHFFFAOYSA-N 2,3,4,5,6-pentafluorobenzenethiol Chemical compound FC1=C(F)C(F)=C(S)C(F)=C1F UVAMFBJPMUMURT-UHFFFAOYSA-N 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 238000000862 absorption spectrum Methods 0.000 claims description 2
- 238000012650 click reaction Methods 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 238000010791 quenching Methods 0.000 abstract description 4
- 238000004220 aggregation Methods 0.000 abstract description 3
- 230000002776 aggregation Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 238000002428 photodynamic therapy Methods 0.000 abstract description 3
- 230000000171 quenching effect Effects 0.000 abstract description 3
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 abstract 2
- 230000008033 biological extinction Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000002211 ultraviolet spectrum Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- YDGMGEXADBMOMJ-LURJTMIESA-N N(g)-dimethylarginine Chemical compound CN(C)C(\N)=N\CCC[C@H](N)C(O)=O YDGMGEXADBMOMJ-LURJTMIESA-N 0.000 description 2
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 description 2
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- 235000008411 Sumatra benzointree Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002130 benzoin Drugs 0.000 description 1
- 150000004035 chlorins Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 230000005693 optoelectronics Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/04—Polysiloxanes
- C08G77/045—Polysiloxanes containing less than 25 silicon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种有机无机杂化光敏剂及杂化纳米诊疗试剂的制备方法,将具有立体笼状结构的聚倍半硅氧烷和十二长烷基链引入到卟啉光敏剂中,通过共沉淀法将光敏剂掺杂入有机半导体纳米粒子中,利用有机半导体高消光系数的特点,作为光能量给体,聚倍半硅氧烷的三维笼状结构有效抑制光敏剂卟啉聚集的同时,还能减轻有机半导体聚集引起的荧光猝灭,同时聚倍半硅氧烷上的十二长烷基链具有增强纳米粒子稳定性的效果,得到的有机无机杂化纳米诊疗剂用于高性能荧光成像指导下的癌症光动力治疗。
Description
技术领域
本发明具体涉及一种有机无机杂化纳米诊疗试剂的制备方法,属于肿瘤诊断和生物医学技术领域。
背景技术
近年来光动力疗法(PDT)由于其无创性,更高的治疗效率和降低全身的毒性,已成为癌症治疗的重要方案之一。当前的光敏剂主要基于卟啉,二氢卟酚及其衍生物,但是这类光敏剂的水溶性差,并且由于其π-π堆积的刚性和疏水性结构的在水溶液中显示出不令人满意的光动力功效和荧光猝灭。另外大多数传统的光敏剂总是具有低吸收截面,这需要较高的光照射功率和高浓度水平的光敏剂。目前明亮的荧光发射和有效的单线态氧生成的结合在图像引导的光动力癌症治疗和光动力抗菌治疗中具有一定性能优越性,但是光动力涉及光敏剂的激发以及随后与氧的系统间交叉相互作用以产生单线态氧,这与荧光发射过程存在争议,且通常会导致量子产率大大降低。
半导体聚合物纳米粒子以其较大的吸收系数、良好的光稳定性和优异的生物相容性,近年来在生物传感、光学成像和光疗等领域引起了广泛的关注。特别是,光捕获和高效的能量传输特性使得它们可以作为光学天线来显著放大光敏剂中的单线态氧的产生。利用这些优点,近年来有机半导体纳米粒子被用于将光敏剂分子物理封装在聚合物基体中,以克服有机光敏剂的水溶性问题,并通过能量传递放大其单线态氧的生成。
然而,当光敏剂分子被包裹在纳米颗粒中时,它们往往会形成聚集体,使整体荧光猝灭,同时也降低了单线态氧的生成能力。另外,小的光敏剂分子容易从纳米粒子中被滤出,导致纳米结构不稳定、光动力效能降低、暗毒性等问题。
发明内容
本发明的目的在于克服现有技术中的不足,提供一种有机无机杂化光敏剂及杂化纳米诊疗试剂的制备方法,制备方法简单,将荧光成像与光动力治疗相结合,增强光敏剂的光动力性能。
为达到上述目的,本发明所采用的技术方案是:
第一方面,本发明公开了一种有机无机杂化光敏剂,结构式如下:
其中R结构式如下:
第二方面,本发明公开了一种有机无机杂化纳米诊疗试剂的制备方法,包括如下制备步骤:
步骤a:以卟啉为主体光敏剂,将具有立体笼状结构的聚倍半硅氧烷和十二长烷基链引入到卟啉光敏剂中,合成有机无机杂化光敏剂;
步骤b:选取与有机无机杂化光敏剂紫外吸收谱在500-600nm处有重叠的有机半导体材料,与步骤a中的有机无机杂化光敏剂混合,共沉淀方法制备纳米粒子。
结合第二方面,所述步骤a是通过点击反应合成有机无机杂化光敏剂。
结合第二方面,可选的,所述步骤b中有机半导体材料包括有机半导体材料PFBT,其吸收波长为480nm,发射波长为560nm,分子式如下:
其中,n为20-30。
第三方面,本发明公开了一种有机无机杂化纳米诊疗试剂,包括上述任一所述的纳米粒子。
第四方面,本发明公开了一种有机无机杂化纳米诊疗试剂的应用,将其应用于图像引导的癌症治疗。
与现有技术相比,本发明所达到的有益效果:
(1)立体笼状结构的聚倍半硅氧烷通过共价连接到卟啉分子上,可以隔离卟啉分子间的距离,增强光敏剂的单线态氧产率;
(2)聚倍半硅氧烷上的十二长烷基链能够增强纳米粒子的稳定性,同时减轻有机半导体聚集引起的荧光猝灭;
(3)强吸光性的有机半导体作为能量给体,显著增强了光敏剂的光动力性能,同时有机半导体作为荧光成像的载体。
附图说明
图1是本发明实施例一种有机无机杂化光敏剂的分子结构式;
图2是本发明实施例有机半导体材料PFBT的分子结构式;
图3是本发明实施例一种有机无机杂化光敏剂与有机半导体材料PFBT共沉淀形成纳米粒子的紫外光谱图;
图4是本发明实施例一种有机无机杂化光敏剂与有机半导体材料PFBT共沉淀形成纳米粒子的荧光光谱图;
图5是本发明实施例一种有机无机杂化光敏剂与有机半导体材料PFBT共沉淀形成纳米粒子的光动力数据图。
具体实施方式
下面结合附图对本发明作进一步描述。以下实施例仅用于更加清楚地说明本发明的技术方案,而不能以此来限制本发明的保护范围。
实施例1
将14.4mg的乙烯基修饰的POSS基卟啉杂化光敏剂,100mg的1-十二烷基硫醇,4mg的安息香双甲醚(DMPA)混合加入500mL的圆底烧瓶中,以干燥的CH2Cl2为溶剂,通氮气15分钟以上,确保整个反应体系在惰性气体氮气的保护下反应,随即使用365nm紫外灯照射60分钟,反应结束后将滤液萃取、干燥、浓缩,并进行色谱法纯化,最终得到一种有机无机杂化光敏剂,其分子结构式如图1所示。
实施例2
如图2所示为有机半导体材料PFBT的分子结构式,选用深圳睿迅光电材料科技有限公司市售的F8BT,产品编号P1213,CAS:210347-52-7,分子量>20000,PDI<3。将实施例1中合成的有机无机杂化光敏剂与有机半导体材料共沉淀形成诊疗试剂纳米粒子,其具体制备流程如下:
a.用四氢呋喃溶解有机无机杂化光敏剂到浓度为0.1mg/mL,避光待用;
b.用四氢呋喃溶解有机半导体材料PFBT,至溶解浓度为0.1mg/mL,避光待用;
c.取1mL步骤b中的PFBT溶液和0.2mL步骤a中的光敏剂溶液混合,添加四氢呋喃至溶液体积6mL,进行超声混合均匀,取2mL溶液在超声状态下快速加入到10mL超纯水中超声7分钟,旋蒸浓缩至2mL,用0.22μm的水相过滤头过滤,得到诊疗试剂纳米粒子,避光4℃保存待用。
实施例3
如图3、图4所示,分别为一种有机无机杂化光敏剂与有机半导体材料PFBT共沉淀形成纳米粒子的紫外光谱图和荧光光谱图,准确配置3mL的诊疗试剂纳米粒子,使用紫外分光光度计去测试其紫外光谱,发现其在340nm和480nm处有有机半导体材料的两个紫外吸收峰,于是诊疗试剂纳米粒子在480nm激发下,在500-600nm会有很强的荧光发射,图示可以表明诊疗试剂纳米粒子具有不错的荧光成像。
实施例4
检测诊疗试剂纳米粒子的光动力效果,首先准确配置3mL的诊疗试剂纳米粒子溶液,取50μL制备好的单线态氧指示剂ADMA加入到溶液中,混合均匀后使用白光(400-700nm)进行光照样品并且每间隔2分钟记录一下材料的紫外吸收峰。
如图5所示,为本发明实施例一种有机无机杂化光敏剂与有机半导体材料PFBT共沉淀形成纳米粒子的光动力数据图,可以看到随着光照时间的延长,ADMA的吸收越来越低,说明诊疗试剂纳米粒子产生的单线态氧增多,具有不错的光动力效果。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明技术原理的前提下,还可以做出若干改进和变形,这些改进和变形也应视为本发明的保护范围。
Claims (6)
2.一种有机无机杂化纳米诊疗试剂的制备方法,其特征在于,包括如下制备步骤:
步骤a:以卟啉为主体光敏剂,将具有立体笼状结构的聚倍半硅氧烷和十二长烷基链引入到卟啉光敏剂中,合成权利要求1所述的有机无机杂化光敏剂;
步骤b:选取与有机无机杂化光敏剂紫外吸收谱在500-600 nm处有重叠的有机半导体材料,与步骤a中的有机无机杂化光敏剂混合,共沉淀方法制备纳米粒子。
3.根据权利要求2所述的一种有机无机杂化纳米诊疗试剂的制备方法,其特征在于,所述步骤a是通过点击反应合成有机无机杂化光敏剂。
5.一种有机无机杂化纳米诊疗试剂,其特征在于,所述试剂包括权利要求2-4任一所述的纳米粒子。
6.如权利要求2-4任一项所述纳米粒子在制备应用于癌症治疗中图像引导的荧光成像的有机无机杂化纳米诊疗试剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010407057.9A CN111569068B (zh) | 2020-05-14 | 2020-05-14 | 一种有机无机杂化光敏剂及杂化纳米诊疗试剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010407057.9A CN111569068B (zh) | 2020-05-14 | 2020-05-14 | 一种有机无机杂化光敏剂及杂化纳米诊疗试剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111569068A CN111569068A (zh) | 2020-08-25 |
CN111569068B true CN111569068B (zh) | 2022-08-30 |
Family
ID=72113606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010407057.9A Active CN111569068B (zh) | 2020-05-14 | 2020-05-14 | 一种有机无机杂化光敏剂及杂化纳米诊疗试剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111569068B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114409679B (zh) * | 2022-01-26 | 2024-01-16 | 南京邮电大学 | 一种靶膜小分子及其制备方法和应用 |
CN115368580B (zh) * | 2022-08-11 | 2023-07-18 | 四川大学华西医院 | 一种基于光敏剂的多孔有机笼状化合物及制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102212195A (zh) * | 2010-04-07 | 2011-10-12 | 韩国科学技术研究院 | 光活性基键合的具有梯子形结构的聚倍半硅氧烷及其制造方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101643295B1 (ko) * | 2014-10-30 | 2016-07-28 | 건국대학교 산학협력단 | 폴리실세스퀴옥산을 코어로 하는 수용성 포르피린집합체 광감작제 및 그 제조방법 |
CN106890341B (zh) * | 2017-03-10 | 2020-09-11 | 东南大学 | 基于化学交联的光疗纳米制剂及其制备方法和应用 |
-
2020
- 2020-05-14 CN CN202010407057.9A patent/CN111569068B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102212195A (zh) * | 2010-04-07 | 2011-10-12 | 韩国科学技术研究院 | 光活性基键合的具有梯子形结构的聚倍半硅氧烷及其制造方法 |
Also Published As
Publication number | Publication date |
---|---|
CN111569068A (zh) | 2020-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Synthesis strategies, luminescence mechanisms, and biomedical applications of near-infrared fluorescent carbon dots | |
Wang et al. | Fe3O4@ MIL-100 (Fe)-UCNPs heterojunction photosensitizer: Rational design and application in near infrared light mediated hypoxic tumor therapy | |
Song et al. | Bioimaging based on fluorescent carbon dots | |
CN108675280B (zh) | 吩噻嗪衍生物荧光碳点及其制备方法和应用 | |
Liu et al. | Boosting the antitumor efficacy over a nanoscale porphyrin-based covalent organic polymer via synergistic photodynamic and photothermal therapy | |
Sun et al. | Protein-assisted synthesis of nanoscale covalent organic frameworks for phototherapy of cancer | |
Lin et al. | A pH-responsive stellate mesoporous silica based nanophotosensitizer for in vivo cancer diagnosis and targeted photodynamic therapy | |
CN111569068B (zh) | 一种有机无机杂化光敏剂及杂化纳米诊疗试剂的制备方法 | |
CN113943305B (zh) | 酞菁荧光分子化合物、制备方法、酞菁荧光纳米材料 | |
CN113773667B (zh) | 有机小分子近红外二区荧光染料及其制备方法和应用 | |
Yang et al. | Increment of the FRET efficiency between carbon dots and photosensitizers for enhanced photodynamic therapy | |
CN109592664B (zh) | 一种具备光激发活性氧产生性能的碳纳米点及其制备方法 | |
Nwahara et al. | Synthesis and photophysical properties of BODIPY-decorated graphene quantum dot–phthalocyanine conjugates | |
Luo et al. | Sn 4+ complexation with sulfonated-carbon dots in pursuit of enhanced fluorescence and singlet oxygen quantum yield | |
CN114015437B (zh) | 一种红光碳量子点及其制备方法 | |
Belik et al. | Synthesis, photophysical properties, and photochemical activity of the water-soluble dyad based on fullerene С 60 and chlorin e 6 derivatives | |
CN113230401A (zh) | 一种核壳上转换MOFs光敏复合材料、制备方法及其应用 | |
Rocha et al. | Graphene oxide–metallophthalocyanine hybrids with enhanced singlet oxygen generation | |
CN110437239B (zh) | 装载四-(n-甲基烯丙基胺)酞菁化合物的金属有机框架材料及制备方法和应用 | |
CN114806211B (zh) | 一种疏水性亚甲蓝荧光染料及其制备方法和应用 | |
CN108421040B (zh) | 兼具双光子成像和光动力疗效的共轭高分子的纳米光敏材料及制备与应用 | |
CN111747398B (zh) | 一种红色碳点材料及其制备方法和应用 | |
CN108578697A (zh) | 一种二氢卟酚e6和四氧化三铁复合纳米粒子的制备方法 | |
Sun et al. | Carbon dots as a novel photosensitizer for photodynamic therapy of cancer and bacterial infectious diseases: recent advances | |
Kuryanova et al. | Effect of amphiphilic polymers on the activity of rose Bengal during the photooxidation of tryptophan in an aqueous medium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |